Laetitia Fend

发表

Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors

L. Zitvogel, L. Galluzzi, G. Kroemer, 2018, Oncoimmunology.

Therapeutic Effects of Anti-CD115 Monoclonal Antibody in Mouse Cancer Models through Dual Inhibition of Tumor-Associated Macrophages and Osteoclasts

J. Marchand, J. Bonnefoy, S. Fournel, 2013, PloS one.

Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death -1 (PD-1) allows their intratumoral delivery and an improved tumor-growth inhibition

L. Zitvogel, J. Marchand, P. Erbs, 2016, Oncoimmunology.

Immune Checkpoint Blockade, Immunogenic Chemotherapy or IFN-α Blockade Boost the Local and Abscopal Effects of Oncolytic Virotherapy.

L. Zitvogel, O. Kepp, G. Kroemer, 2017, Cancer research.

Prognostic impact of the expression of NCR1 and NCR3 NK cell receptors and PD-L1 on advanced non-small cell lung cancer

L. Zitvogel, G. Kroemer, J. Adam, 2017, Oncoimmunology.

Shaping the tumor microenvironment with Modified Vaccinia Virus Ankara and TLR9 ligand

K. Rittner, Laetitia Fend, X. Préville, 2015, Oncoimmunology.

Oncolytic virotherapy with an armed vaccinia virus in an orthotopic model of renal carcinoma is associated with modification of the tumor microenvironment

J. Foloppe, P. Erbs, S. Fournel, 2015, Oncoimmunology.

By Binding CD80 and CD86, the Vaccinia Virus M2 Protein Blocks Their Interactions with both CD28 and CTLA4 and Potentiates CD80 Binding to PD-L1

J. Marchand, J. Foloppe, P. Erbs, 2019, Journal of Virology.

Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy

M. Delorenzi, L. Pusztai, L. Zitvogel, 2014, Nature Medicine.

TLR2 ligation protects effector T cells from regulatory T-cell mediated suppression and repolarizes T helper responses following MVA-based cancer immunotherapy

J. Bonnefoy, S. Muller, K. Rittner, 2012, Oncoimmunology.

TNFR2/BIRC3-TRAF1 signaling pathway as a novel NK cell immune checkpoint in cancer

L. Zitvogel, G. Kroemer, P. Validire, 2017, Oncoimmunology.

Vectorized Treg-depleting αCTLA-4 elicits antigen cross-presentation and CD8+ T cell immunity to reject ‘cold’ tumors

J. Marchand, J. Foloppe, Jules Deforges, 2022, Journal for ImmunoTherapy of Cancer.

Intravenous Injection of MVA Virus Targets CD8+ Lymphocytes to Tumors to Control Tumor Growth upon Combinatorial Treatment with a TLR9 Agonist

S. Fournel, K. Rittner, Laetitia Fend, 2014, Cancer Immunology Research.

Abstract 5602: BT-001, an oncolytic vaccinia virus armed with a Treg-depletion-optimized recombinant human anti-CTLA4 antibody and GM-CSF to target the tumor microenvironment

J. Marchand, J. Foloppe, B. Frendéus, 2020 .

Intravenous injection of a modified vaccinia ankara virus induces intratumoral CD8+ lymphocyte infiltration favoring tumor control in an orthotopic tumor model upon combinatorial treatment with a TLR9 agonist

S. Fournel, K. Rittner, Laetitia Fend, 2014, Journal of Immunotherapy for Cancer.

BT-001, AN ONCOLYTIC VACCINIA VIRUS ARMED WITH A TREG-DEPLETING HUMAN RECOMBINANT ANTI-CTLA4 ANTIBODY AND GM-CSF TO TARGET THE TUMOR MICROENVIRONMENT

B. Frendéus, I. Teige, Laetitia Fend, 2020 .